We are excited to announce the formation of our inaugural Board of Directors—a pivotal milestone in our journey to deliver innovative biometric solutions, achieve operational excellence, and expand our global reach.
Joining our newly established board are Bryan Katz and Calvin Liou, both seasoned leaders with extensive expertise in clinical research, healthcare strategy, and operational leadership.
“Establishing a Board of Directors reflects our growth and the need for strong strategic guidance as we advance our mission to provide exceptional biometric solutions for the clinical trials industry,” said Amir Malka, our CEO and Co-Founder. “Bryan and Calvin bring invaluable industry insights, proven leadership, and unique perspectives that will help drive our continued success and expansion.”
Bryan Katz, CEO of PharmaStreet Research and a senior Pharma Life Science advisor, has an impressive track record in deal strategy, innovation, and enabling technologies within pharmaceutical services and clinical research. His previous leadership roles at ProPharma, Syneos Health, KCR, IQVIA, PwC, and Abbott Laboratories position him to bolster our growth strategy, industry partnerships, and go-to-market initiatives.
Calvin Liou, a highly accomplished healthcare investor, brings expertise in scaling organizations and fostering growth. With prior board experience and a decade as an investment banker and private equity professional, Calvin is well-versed in driving success for healthcare companies. He is the founder of Olive Tree GP, a healthcare and technology-focused merchant bank, following his tenure as Senior Vice President at TA Associates.
This significant step comes as we continue to expand our comprehensive suite of biometric services, including data management, biostatistics, statistical programming, and medical writing. Through proprietary technology solutions like BioGrid (visual analytics), JetConvert (SDTM conversion), and Validify (risk analysis and validation), we remain committed to helping our clients accelerate clinical development with reliable, high-quality data.
“I’m honored to join the Board of Directors and contribute to the continued growth and leadership of this exceptional team in the biometrics space,” said Katz. Liou added, “Our commitment to innovation and excellence positions us as a standout partner for clinical research organizations worldwide. I look forward to supporting this ambitious vision.”